| 2026-09-23 | 8-K | 10.3 | Guaranty and Security Agreement, dated as of September 23, 2026, by and among Clover Finance Trust, Clover Finance LLC, Theravance Biopharma Ireland Limited, Theravance Biopharma US, LLC, Theravance Biopharma R&D IP, LLC, Theravance Biopharma Antibiotics IP, LLC, and U.S. Bank Trust Company, National Association, as Agent. |
|---|
| 2026-09-23 | 8-K | 10.2 | Note Purchase Agreement, dated as of September 23, 2026, by and among Clover Finance Trust, Clover Finance LLC, OCM IP Healthcare Portfolio LP, and U.S. Bank Trust Company, National Association, as Agent. |
|---|
| 2026-09-23 | 8-K | 10.1 | Contingent Value Rights Agreement, dated as of September 22, 2026, by and among Zymeworks Inc., Computershare and Computershare Trust Company, N.A., acting jointly with Computershare, as Rights Agent. |
|---|
| 2026-08-06 | 10-Q | 10.4 | Employment Agreement between Zymeworks Biopharmaceuticals Inc. and Paul Schneider, effective May 13, 2026. |
|---|
| 2026-06-29 | 8-K | 10.1 | Form of Contingent Value Rights Agreement. |
|---|
| 2026-05-07 | 10-Q | 10.5 | Employment Agreement between Zymeworks Biopharmaceuticals Inc. and Scott Platshon, effective April 9, 2026 |
|---|
| 2026-05-07 | 10-Q | 10.4 | Employment Agreement between Zymeworks Biopharmaceuticals Inc. and Adam Schayowitz, effective April 9, 2026 |
|---|
| 2026-05-07 | 10-Q | 10.2 | Loan Agreement by and among Zymeworks Royalty Limited Partnership Royalty Pharma Development Funding, LLC and the Lenders from time to time party thereto dated as of March 2, 2026. |
|---|
| 2026-05-07 | 10-Q | 10.1 | Sale Agreement by and among Zymeworks BC Inc., Zymeworks Royalty Limited Partnership, Zymeworks Inc., and Royalty Pharma Development Funding, LLC dated as of March 2, 2026. |
|---|
| 2026-04-01 | 8-K | 10.1 | Employment Agreement between Zymeworks Biopharmaceuticals Inc. and Kristin Stafford, effective April 1, 2026 |
|---|
| 2026-03-02 | 10-K | 10.59 | Separation Agreement and Release, by and between Leone Patterson and Zymeworks Biopharmaceuticals, Inc., dated February 1, 2026. |
|---|
| 2026-03-02 | 10-K | 10.58 | Severance Agreement, Consultancy Agreement, and Assignment and Novation Agreement by and among Zymeworks Pharmaceuticals Limited, Zymeworks BC Inc., and Jeffrey Smith dated January 31, 2026. |
|---|
| 2026-03-02 | 10-K | 10.57 | Employment Agreement by and between Dr. Sabeen Mekan and Zymeworks Biopharmaceuticals Inc., effective as of April 21, 2025. |
|---|
| 2026-03-02 | 10-K | 10.56 | Employment Agreement by and between Mark Hollywood and Zymeworks Biopharmaceuticals Inc., effective as of March 25, 2019. |
|---|
| 2026-03-02 | 10-K | 10.55 | Three-Party Royalty Payment Agreement by and among Zymeworks BC Inc., BeOne Medicines Ltd., and BeOne Pharmaceutical (Suzhou) Co., Ltd., dated October 30, 2025. |
|---|
| 2025-08-11 | 8-K | 10.1 | Stock Purchase Agreement, dated August 10, 2025, by and between the Company and Gregory Ciongoli |
|---|
| 2025-08-07 | 10-Q | 10.2 | First Amendment to Research License and Commercial Option Agreement, effective July 7, 2025, by and among Merck Sharp & Dohme LLC, Intervet International B.V., and Zymeworks BC Inc. |
|---|
| 2025-06-27 | 8-K | 10.1 | Amendment No. 1 to Pre-Funded Warrants to Purchase Shares of Common Stock, dated June 26, 2025 by and among the Company and the Purchasers. |
|---|
| 2025-05-08 | 10-Q | 10.1 | Fifth Amendment to Collaboration Agreement, effective March 3, 2025, by and between Zymeworks BC Inc. and Celgene Corporation. |
|---|
| 2024-10-31 | 10-Q | 10.4 | Direction to Tenants, dated July 9, 2024, from 130 E 4th(2) Partnership, 130 E 4th Property Inc., and 114 East 4th Avenue, LLC to Tenants of 114 East 4th Avenue, Vancouver, BC |
|---|
| 2024-08-01 | 10-Q | 10.2 | Amended and Restated Stock Option and Equity Compensation Plan of the Company (and forms of agreements thereunder) and UK Sub-Plan to the Amended and Restated Stock Option and Equity Compensation Plan of the Company (and forms of agreements thereunder). |
|---|
| 2024-07-25 | 8-K | 10.2 | Amended and Restated Inducement Stock Option and Equity Compensation Plan (and forms of award agreements thereunder) |
|---|
| 2024-07-25 | 8-K | 10.1 | Employment Agreement between Zymeworks Biopharmaceuticals Inc. and Leone Patterson, dated July 19, 2024 |
|---|
| 2024-04-04 | 8-K | 10.1 | Separation Agreement and Release by and between Zymeworks BC Inc. and Christopher Astle, dated April 3, 2024. |
|---|
| 2024-03-06 | 10-K | 10.50 | Amended and Restated Stock Option and Equity Compensation Plan of the Company (and forms of agreements thereunder) and UK Sub-Plan to the Amended and Restated Stock Option and Equity Compensation Plan of the Company (and forms of agreements thereunder). |
|---|
| 2024-03-06 | 10-K | 10.49 | Inducement Stock Option and Equity Compensation Plan of the Company (and forms of agreements thereunder). |
|---|
| 2024-03-06 | 10-K | 10.43 | Letter, dated January 5, 2024, from Zymeworks Inc. to Jeffrey Smith. |
|---|
| 2024-03-06 | 10-K | 10.42 | Employment Agreement by and between Zymeworks Pharmaceuticals Limited and Jeffrey Smith, dated January 3, 2023. |
|---|
| 2024-01-05 | 8-K | 10.1 | Amendment #2 to Employment Agreement, dated as of January 3, 2024, by and among Kenneth Galbraith and Zymeworks BC Inc. |
|---|
| 2023-12-26 | 8-K | 10.3 | Form of Pre-Funded Warrant. |
|---|
| 2023-12-26 | 8-K | 10.2 | Registration Rights Agreement, dated December 23, 2023, by and among the Company and the Purchasers. |
|---|
| 2023-12-26 | 8-K | 10.1 | Securities Purchase Agreement, dated December 23, 2023, by and among the Company and the Purchasers. |
|---|
| 2023-11-07 | 10-Q | 10.4 | Amended and Restated Stock Option and Equity Compensation Plan of the Company (and forms of agreements thereunder) and UK Sub-Plan to the Amended and Restated Stock Option and Equity Compensation Plan of the Company (and forms of agreements thereunder). |
|---|
| 2023-09-21 | 8-K | 10.2 | Third Amendment License and Collaboration Agreement by and between Zymeworks BC Inc. and BeiGene, Ltd., dated September 18, 2023. |
|---|
| 2023-09-21 | 8-K | 10.1 | Termination Agreement by and between Zymeworks BC Inc. and BeiGene, Ltd., dated September 18, 2023. |
|---|
| 2023-08-10 | 10-Q | 10.5 | Amendment No. 1 to Stock and Asset Purchase Agreement, dated May 15, 2023, by and between Zymeworks BC Inc., Zymeworks Biopharmaceuticals Inc., Zymeworks Zanidatamab Inc., and Jazz Pharmaceuticals, Inc. |
|---|
| 2023-08-10 | 10-Q | 10.4 | Stock and Asset Purchase Agreement, dated April 25, 2023, by and between Zymeworks BC Inc., Zymeworks Biopharmaceuticals Inc., Zymeworks Zanidatamab Inc., and Jazz Pharmaceuticals, Inc. |
|---|
| 2023-08-10 | 10-Q | 10.2 | Amended and Restated Employment Agreement by and between Zymeworks BC Inc., the Company and Paul Moore, dated July 14, 2023. |
|---|
| 2023-05-18 | 8-K | 10.1 | Separation Agreement and Release by and between Zymeworks BC Inc. and Neil Klompas, dated May 17, 2023. |
|---|
| 2023-05-16 | 8-K | 10.1 | Amended and Restated License and Collaboration Agreement, dated May 15, 2023, by and between Zymeworks BC Inc. and Jazz Pharmaceuticals Ireland Limited. |
|---|
| 2023-05-08 | 10-Q | 10.2 | Termination and License Agreement by and between Zymeworks BC Inc. and Daiichi Sankyo Co., Ltd., effective as of February 28, 2023. |
|---|
| 2023-03-07 | 10-K | 10.74 | License and Collaboration Agreement, dated October 18, 2022, by and between Zymeworks BC Inc. and Jazz Pharmaceuticals Ireland Limited. |
|---|
| 2023-03-07 | 10-K | 10.64 | Executive Incentive Compensation Plan. |
|---|
| 2023-03-07 | 10-K | 10.59 | Separation and Release Agreement by and between Zymeworks Biopharmaceuticals Inc. and Neil Josephson, dated March 3, 2023. |
|---|
| 2022-12-30 | 8-K | 10.1 | Amendment to Employment Agreement, dated as of December 30, 2022, by and among Kenneth Galbraith, Zymeworks BC Inc. and Zymeworks Management Inc. |
|---|
| 2022-11-18 | 8-K | 10.1 | Amendment to Amended and Restated Employment Agreement, by and between Christopher Astle and Zymeworks BC Inc., dated November 17, 2022. |
|---|